Table 2:

Activity outcomes (overall cohort and subgroups)

	Overall response		Clinical benefit		Median time to treatment failure	12-month overall survival
	n/N	% (95% CI)	n/N	% (95% CI)
Overall cohort	30/112	27% (19–36)	83/112	74% (65–82)	6·7 (5·5– 8·6)	51% (39–62)
Histology
Papillary	18/66	27% (17–40)	48/66	73% (60–83)	6·9 (4·6–10·1)	46% (31–60)
Xp11.2 translocation	5/17	29% (10–56)	14/17	82% (57–96)	8·3 (4·6–NR)	69% (36–87)
Unclassified	2/15	13% (2–40)	10/15	67% (38–88)	6·0 (1·4–9·9)	36% (8–67)
Chromophobe	3/10	30% (7–65)	7/10	70% (35–93)	5·7 (1·1–7·8)	60% (16–87)
Collecting duct	2/4	50% (7–93)	4/4	100% (40–99)	NC	NC
Sarcomatoid features
Yes	6/30	20% (8–39)	23/30	77% (58–90)	5·1 (2·8–6·2)	25% (8–47)
No	13/51	25% (14–40)	34/51	67% (52–79)	7·4 (4·6–11·0)	48% (31–64)
Treatment
First line	5/22	23% (8–45)	18/22	82% (60–95)	7·6 (5·5–17·2)	60% (29–81)
Second line or more	25/90	28% (19–38)	65/90	72% (62–81)	6·2 (4·6–8·6)	49% (36–61)
Type of previous systemic therapies
Immunotherapy	4/12	33% (10–65)	10/12	83% (52–98)	5·1 (1·8–7·8)	27% (1–66)
Tyrosine kinase inhibitor	11/39	28% (15–45)	24/39	62% (45–77)	6·2 (3·4–10·6)	54% (36–70)
Tyrosine kinase inhibitor and immunotherapy	10/36	28% (14–45)	28/36	78% (61–90)	6·9 (4·6–11·0)	48% (28–66)
Other	0/3	0	3/3	100% (29–99)	NC	NC
IMDC risk group
Favourable	5/9	56% (21–86)	8/9	89% (52–99)	11·0 (6·2–NR)	67% (19–90)
Intermediate	15/71	21% (12–32)	52/71	73% (61–83)	6·0 (4·6–7·8)	51% (36–64)
Poor	9/29	31% (15–51)	21/29	72% (53–87)	8·0 (3·7–15·9)	46% (23–66)
Presence of bone metastasis*
Yes	10/49	20% (10–34)	38/49	78% (63–88)	6·9 (4·8–9·0)	44% (27–60)
No	20/63	32% (21–45)	45/63	71% (59–82)	6·4 (4·6–11·0)	57% (41–71)

Data are n/N, % (95% CI), or months (95% CI). NR=not reached. NC=not calculated (too few patients to calculate reliably). IMDC=International Metastatic Renal Cell Carcinoma Database Consortium.

^*All patients with bone metastasis also had either lymph node or visceral metastases.